Literature DB >> 10065419

Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor.

R Hayman1, J Brockelsby, L Kenny, P Baker.   

Abstract

It has been proposed that endothelial cell activation is the primary event in the multisystem disorder of preeclampsia. Evidence for endothelial involvement in this condition abounds. The best-characterized morphologic abnormality of this syndrome, glomerular endotheliosis, involves endothelial cells. Also associated with preeclampsia is a loss of endothelial cell integrity, with the consequent increase in vascular permeability, and an increase in the circulating levels of the endothelial cell markers, fibronectin, von Willebrand factor, tissue plasminogen activator, and plasminogen activator inhibitor-1. It is now well documented that endothelial activation contributes to the coagulation abnormalities observed in this disease. There is much evidence that the endothelial alterations in preeclampsia result from one or more circulating factors. The incubation of cultured endothelial cells with serum or plasma samples, taken from normal pregnant women and women with preeclampsia, results in marked alterations in cell behavior and metabolic processes. More recently, experiments employing myographic techniques have demonstrated convincingly the effects of a circulating factor(s) on the function of endothelial cells of resistance arteries. Vascular endothelial growth factor (VEGF) possesses many of the characteristics required of a candidate circulating factor. It contains a hydrophobic secretory signal sequence, exerts in vitro effects specific to vascular endothelial cell, and promotes endothelial expression of procoagulant activity. Circulating VEGF concentrations are elevated in women with preeclampsia, and VEGF increases microvascular endothelial cell prostacyclin production in a dose-dependent manner, analogous to the acute effects of plasma from patients with preeclampsia. Similarly, in myographic studies, when myometrial resistance arteries are incubated with VEGF, there are dose-dependent alterations in endothelium-dependent behavior, mirroring those found after incubation with plasma from patients with preeclampsia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065419

Source DB:  PubMed          Journal:  J Soc Gynecol Investig        ISSN: 1071-5576


  12 in total

1.  [Ca2+]i signaling vs. eNOS expression as determinants of NO output in uterine artery endothelium: relative roles in pregnancy adaptation and reversal by VEGF165.

Authors:  Fu-Xian Yi; Derek S Boeldt; Ronald R Magness; Ian M Bird
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-14       Impact factor: 4.733

2.  Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma.

Authors:  A M Gil-Villa; L V Norling; C N Serhan; D Cordero; M Rojas; A Cadavid
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2012-09-10       Impact factor: 4.006

Review 3.  eNOS activation and NO function: pregnancy adaptive programming of capacitative entry responses alters nitric oxide (NO) output in vascular endothelium--new insights into eNOS regulation through adaptive cell signaling.

Authors:  D S Boeldt; F X Yi; I M Bird
Journal:  J Endocrinol       Date:  2011-05-09       Impact factor: 4.286

4.  Contribution of PARP to endothelial dysfunction and hypertension in a rat model of pre-eclampsia.

Authors:  S K Walsh; F A English; I P Crocker; E J Johns; L C Kenny
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

5.  Vascular endothelial growth factor acts through novel, pregnancy-enhanced receptor signalling pathways to stimulate endothelial nitric oxide synthase activity in uterine artery endothelial cells.

Authors:  Mary A Grummer; Jeremy A Sullivan; Ronald R Magness; Ian M Bird
Journal:  Biochem J       Date:  2009-01-15       Impact factor: 3.857

6.  Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS.

Authors:  D Maroeska Te Loo; Nienke Bosma; Victor Van Hinsbergh; Paul Span; Rob De Waal; Ruud Clarijs; C Sweep; Leo Monnens; Lambertus Van Den Heuvel
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

7.  CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia?

Authors:  Francesca Gotsch; Roberto Romero; Lara Friel; Juan Pedro Kusanovic; Jimmy Espinoza; Offer Erez; Nandor Gabor Than; Pooja Mittal; Samuel Edwin; Bo Hyun Yoon; Chong Jai Kim; Shali Mazaki-Tovi; Tinnakorn Chaiworapongsa; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2007-11

8.  Pro-inflammatory profile of preeclamptic placental mesenchymal stromal cells: new insights into the etiopathogenesis of preeclampsia.

Authors:  Alessandro Rolfo; Domenica Giuffrida; Anna Maria Nuzzo; Daniele Pierobon; Simona Cardaropoli; Ettore Piccoli; Mirella Giovarelli; Tullia Todros
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

9.  Role of dyslipidemia in preeclamptic overweight pregnant women.

Authors:  Seyede Hajar Sharami; Azita Tangestani; Roya Faraji; Ziba Zahiri; Azam Amiri
Journal:  Iran J Reprod Med       Date:  2012-03

10.  Carbon monoxide prevents hypertension and proteinuria in an adenovirus sFlt-1 preeclampsia-like mouse model.

Authors:  Carolina C Venditti; Richard Casselman; Iain Young; S Ananth Karumanchi; Graeme N Smith
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.